Microbot Medical Inc
Microbot Medical Inc (MBOT) Covered Calls
Microbot Medical Inc trades in the Medical Devices industry with an IV Rank of 94.84%, high versus the past year. MBOT's highest covered call setup is the $5.00 strike expiring Jan 21, 2028, sorted by theoretical annualized return. It's 380.77% out of the money with 445 days to expiration, a 385.58% return until expiration, and a 316.26% theoretical annualized return. Across the setups shown, annualized returns run from 40.22% to 316.26% at strikes between $1.50 and $5.00, with 165 to 445 days to expiration, as of Nov 2, 2026.
Read more
Running MBOT covered calls helps you generate income from Microbot Medical Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best MBOT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If MBOT stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling MBOT covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given MBOT covered call is worth writing.
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development.
| 2028-01-21 | 445 | 5.00 | 380.77 | 0.05 | 0.45 | 401.00 | 385.58 | 316.26 | -4.81 | +0.42 | 2,168 | 0.40 |
| 2028-01-21 | 445 | 2.50 | 140.38 | 0.25 | 0.35 | 171.00 | 164.42 | 134.86 | -24.04 | +0.51 | 3,892 | 0.10 |
| 2027-04-16 | 165 | 1.50 | 44.23 | 0.10 | 0.25 | 56.00 | 53.85 | 119.11 | -9.62 | +0.45 | 178 | 0.15 |
| 2028-01-21 | 445 | 2.00 | 92.31 | 0.15 | 0.40 | 111.00 | 106.73 | 87.54 | -14.42 | +0.51 | 2,303 | 0.25 |
| 2028-01-21 | 445 | 1.50 | 44.23 | 0.05 | 0.80 | 51.00 | 49.04 | 40.22 | -4.81 | +0.66 | 248 | 0.75 |
As of Nov 2, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →Stock Statistics
- IndustryMedical Devices
- SectorHealthcare
- IV Rank94.84% High
- Market cap (M$)73
- 52 weeks high-61.89%
- 52 weeks low17.20%
- Analyst recommendationStrong Buy
1.00 - Target price$5.38
393.58% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-11
- P/E—
- Future P/E—
- EPS (ttm)-0.26
- EPS growth next 5 years8.80%
As of Nov 3, 2026